Welcome to our dedicated page for Transmedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on Transmedics Group stock.
TransMedics Group, Inc. reports developments in medical technology for organ transplant therapy, centered on its Organ Care System, or OCS, for preserving and monitoring donor lungs, hearts and livers outside the body. Company updates commonly cover OCS utilization through the National OCS Program, transplant logistics services, aviation fleet capacity, revenue trends and margin drivers.
Recurring news also includes clinical and regulatory disclosures tied to OCS programs and the Controlled Hypothermic Organ Preservation System, tax-accounting updates, material agreements, governance actions and employee equity awards. These developments reflect the company's commercial-stage model in organ preservation, transplant logistics and transplant-service support.
TransMedics Group, Inc. (Nasdaq: TMDX) announced that its management team will engage in a virtual fireside chat during the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 4:30 p.m. ET. This discussion will be accessible via a live and archived webcast in the Investors section of the TransMedics website. Based in Andover, Massachusetts, TransMedics is pioneering portable organ perfusion technology to enhance organ transplantation outcomes, addressing critical needs in heart, lung, and liver failure treatment.
TransMedics Group, Inc. (TMDX), a leader in organ transplant technology, will release its second quarter financial results on August 5, 2021, after market close. The management team will host a conference call at 4:30 p.m. ET. Interested investors can join by dialing (833) 378-1026 or (236) 712-2500 for international calls. TransMedics focuses on improving organ quality and viability assessments, addressing the critical need for better organ transplants for patients with end-stage heart, lung, and liver failure.
TransMedics Group, Inc. (Nasdaq: TMDX) announced a positive FDA advisory committee vote for the OCS Liver System on July 14, 2021. The panel voted 14-0 for effectiveness and safety, with a 12-1 vote indicating the benefits outweigh risks. This milestone moves TransMedics closer to potential FDA approval, which could enhance liver transplant outcomes for patients with end-stage liver failure. The OCS Liver PROTECT trial showed significant improvements in early allograft dysfunction, utilization of donor livers, and patient survival rates.
TransMedics Group, Inc. (Nasdaq: TMDX) announced on July 14, 2021, that trading of its common stock has been halted by Nasdaq. The halt coincides with a meeting of the FDA's Gastroenterology and Urology Devices Panel, which is set to review TransMedics' Organ Care System™ (OCS) Liver System. This medical device aims to preserve donor liver organs in a near-physiologic state, enhancing their viability for transplantation. Investors are advised to monitor the outcome of the FDA meeting as it may impact future stock performance.
TransMedics Group, Inc. (TMDX), based in Andover, Massachusetts, announced a public advisory committee meeting by the FDA scheduled for July 14, 2021. This meeting will discuss the premarket approval application for the OCS Liver System. The FDA's Gastroenterology and Urology Devices Panel will review the system, which aims to improve organ transplant therapy for patients with end-stage organ failure. CEO Waleed Hassanein highlighted this as a key milestone in obtaining FDA approvals for their organ platforms in 2021.
Summary not available.
TransMedics Group, Inc. (TMDX) reported a net revenue of $7.1 million for Q1 2021, marking a 6% decline from Q1 2020. However, U.S. net revenue rose by 11% year-over-year, totaling $5.8 million. The increase was attributed to strong sales in OCS Lung and OCS Heart, although these gains were partially offset by reduced OCS Liver activity. Gross margin improved to 68%, and operating expenses decreased to $11.3 million. The net loss narrowed to $7.9 million. The company remains optimistic about future FDA approvals for its OCS systems.
TransMedics Group, Inc. (Nasdaq: TMDX) will release its first-quarter financial results on May 4, 2021, after market close. A conference call will follow at 4:30 p.m. ET for investors to discuss the results. The company specializes in advanced organ transplant technologies aimed at improving donor organ quality and viability assessment for heart, lung, and liver transplants. Investors can access the call by phone or via the live webcast on the company's website.
TransMedics Group (Nasdaq: TMDX) announced a favorable vote from the FDA Circulatory Systems Device Advisory Panel on April 6, 2021, for its OCS Heart System. The panel supported the device's benefits over risks with a vote of 12 to 5 and indicated reasonable assurance of its effectiveness and safety. The OCS Heart EXPAND trial achieved a primary effectiveness endpoint, successfully transplanting 84% of extended-criteria donor hearts. The company is optimistic about future FDA approval and plans to expand its heart transplantation capabilities.
TransMedics Group, Inc. (NASDAQ: TMDX) announced a halt in trading of its common stock as the FDA's Circulatory System Devices Panel meets to review its Organ Care System™ (OCS) Heart System. The OCS™ is designed to preserve a donated heart in a near-physiologic state for monitoring and eventual transplantation. The meeting is set for 9:00 a.m. ET, with more details available on the FDA's website. This review is crucial for advancing TransMedics' innovative technology aimed at improving organ transplantation outcomes.